{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 42,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes a waterfall plot for the BEGONIA trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/32",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Phase Ib/II BEGONIA Dato-DXd + Imfinzi in 1L adv/met TNBC",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "405af704-5a56-4aac-9d03-335c2f59f695",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "Potential in heavily pre-treated HR+/HER2- Phase I TROPION-PanTumor01: Encouraging efficacy, ORR 27%, DCR 85%, mPFS 8.3m. Phase III ongoing.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a30dbd4b-8cdd-4443-9239-c3e62fd17f9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.52,
        "y": 0.22
      },
      "kind": "list",
      "text": "Potential to address advanced TNBC Phase I TROPION-PanTumor01: mDOR 16.8m, ORR 32% (44% in naive), 6mg/kg dose validated.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee67aae8-cd45-48f3-97a3-93b891b3e3c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.52,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "4 patients observed complete response, with responses observed in PDL1-high and low tumours",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd183b77-d9f6-4e2c-8a8c-4b156fcd045a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Dato-DXd = datopotamab deruxtecan; ADC = antibody drug conjugate; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple negative breast cancer; ORR = overall response rate; mDOR = median duration of response; BICR = blinded independent central review; DCR = disease control rate; mPFS = median progression free survival; PDL-1 = programmed death-ligand 1.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29b280d3-e260-4067-8da1-1a5f8a14d2cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Reinforcing potential of next-gen ADCs to replace chemo across HR+ and TNBC",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3685a19d-59e4-461d-9ea7-3c743e642333",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.18,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Dato-DXd",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96b220cc-d561-4784-bf6f-1ff25278f76c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "704cbe41-1cf5-410f-a01f-2945edbc79f8",
      "evidence": "chart/waterfall: Phase Ib/II BEGONIA Dato-DXd + Imfinzi in 1L adv/met TNBC",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 37,
      "from": 30,
      "beatId": "88b7703b-c29f-499c-87c5-dd04e5a0e55a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Other key data, Enhertu, and capivasertib",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}